**Article:**
Catalent has announced plans to close its cell therapy and plasmid manufacturing site located in Gosselies, Belgium. The decision was reported by local media and is part of the company’s broader operational adjustments. The closure will impact the production of cell therapy products and plasmids at the facility.
The company has not yet provided detailed information on the timeline for the shutdown or the number of employees affected. Catalent is expected to reallocate resources and focus on other sites to maintain its manufacturing capabilities.
**Why this matters:**
The closure of the Gosselies site could affect the supply chain for cell therapy products, which are critical in advanced medical treatments. As Catalent is a major player in biopharmaceutical manufacturing, changes to its operations may influence the availability and development of innovative therapies. This move also highlights ongoing shifts in the pharmaceutical manufacturing landscape in Europe.
Source: NewsData